Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis

Amgen, 04/06/2012

UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

Print Article Summary